1
|
Al-Saleh KA, El Zawahry HM, Bounedjar A, Oukkal M, Saadeddin A, Mahfouf H, Kamel B, Bensalem A, Abdel-Razeq H, Kandil A, Abulkhair OAM, Al-Foheidi MO, Ghosn M, Boussen H, Haddaoui A, Ayari JB, Alghamdi M, Abdulaziz NA, Kullab SA, Nabholtz JMA. Final result for SAFIA trial for neoadjuvant palbociclib in patients with operable luminal breast cancer responding to fulvestrant. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.16_suppl.596] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
596 Background: Luminal, human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC) encompasses the most common subtype of breast malignancies. Neoadjuvant strategies of operable BC are primarily based upon chemotherapy (CT), while neoadjuvant hormone therapy (NAHT) has not been well studied in the Middle East and North Africa (MENA) region. However, these tumors might respond poorly to neoadjuvant CT with significant side effects, emphasizing the need to identify patients who could be candidates for NAHT. Methods: The SAFIA trial is a prospective multicentre, international, double-blind, neoadjuvant phase-III trial using upfront 21-gene Oncotype DX Breast Recurrence Score assay (RS) <31) to select operable Luminal HER2-negative patients for induction hormonal therapy with Fulvestrant 500 mg +/– Goserelin (F/G) before randomizing responding patients to F/G + Palbociclib (Cyclin-Dependent Kinase 4/6 inhibitor / CDK 4/6) versus F/G + Placebo. The primary endpoint of this study was the complete pathologic response (pCR) rate. Results: A total of 354 patients were enrolled, leading to 277 patients treated with induction F/G. Of these, 253 responding patients were randomized to F/G fulvestrant with palbociclib or Placebo. Two hundred and thirty patients were evaluable for pathologic response. No statistically significant differences were identified in terms of pCR rates between F/G with palbociclib or placebo: 2% versus 7%, respectively. According to the radiologic responses post- induction F/G, the hormone sensitivity rate was 89.8%, while the clinical benefit of 8–9 months of neoadjuvant F/G was 96%. Safety in the MENA population was acceptable with a grade 3-4 neutropenia rate of 25% in the F/G plus palbociclib arm. The feasibility of performing the 21-gene breast recurrence score assay on core biopsy specimens was optimal in 96.4% of cases. Conclusions: The addition of palbociclib to neoadjuvant F/G did not show any additional benefit in terms of pathologic response, including pCR in neoadjuvant therapy of Luminal HER2-negative BC responding to induction F/G. The use of an upfront 21-gene assay appeared feasible on biopsy specimens, and the identification of tumors with RS<31 allowed to select endocrine sensitive patients, leading ultimately to a 96% clinical benefit with 8–9 months of F/G neoadjuvant therapy. Clinical trial information: NCT03447132. [Table: see text]
Collapse
Affiliation(s)
| | | | - Adda Bounedjar
- Université Blida 1Laboratoire de cancérologie, Faculté de Médecine, Blida, Algeria
| | | | | | | | | | | | | | - Alaa Kandil
- Alexandria University Hospital, Alexandria, Egypt
| | | | - Meteb Owaish Al-Foheidi
- Princess Noorah Oncology Center, King Saud bin Abdulaziz University (Jeddah), Jeddah, Saudi Arabia
| | | | | | - Abderrazak Haddaoui
- Université De Tunis El Manar, Faculté de Médecine de Tunis, Tunisie the Military Hospital of Tunis, Department of Medical Oncology, Mont Fleury, Tunisia
| | | | | | | | | | | |
Collapse
|
2
|
Ayari JB, Haj Ammar S, Balti M, Ben Azaiz M, Zribi A, Fendri S, Ben Nasr S, Ghazouani E, Agili F, Kullab SA, Haddaoui A. Prognostic value of circulating cytokines in breast cancer: A prospective study in sixty breast cancer patients in Tunisia. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.e12592] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e12592 Background: Breast cancer is the second most common cancer and the fifth most common cause of cancer mortality worldwide. The functional relationship between inflammation and cancer is an old concept of cancero- genesis, and it is now clear that inflammatory process certainly potentiates and/or promotes neoplastic risk. However, many of the molecular and cellular mechanisms mediating this relationship remain unresolved. The aim of this study is to measure the level of circulating cytokines (IL17, IL6, IL22, IL23 and TNFα) in breast cancer patients in Tunisia, and to evaluate their implication as prognostic factors. Methods: Serum samples were collected prospectively from sixty breast cancer patients in Tunisia. TNF-α and IL6 levels were determined using the technique of a solid-phase, two-site chemo-luminescent enzyme immune-metric assay (Immulite 1000, USA). Serum levels of IL17, IL22 and IL23 were measured by enzyme-linked immunosorbent assays (ELISA) sandwich method. Results: The mean age of patients is 48 years, and fourth of them were metastatic. The mean level of cytokines IL6, IL17, TNFα, IL22 and IL23 were respectively 4.80 ± 7.26 pg/ ml (min 2, max 36.80 pg/ ml), 0.27 ± 0.69 pg/ ml (min 0, max 3.62 pg/ ml), 5.93 ± 2.27 pg/ ml (min 4, max 15.30 pg/ml), 50.82 ± 34.78 p/ml (min 26.48, max 199.48 pg/ ml) and 18.05 ± 30.91 pg/ ml (min 0, max 200.21 pg/ml). Serum IL6 level was significantly higher in advanced stages (p = 0.013), especially in metastatic cases (p = 0.001) and in patients who had recurrent disease (p = 0.010). High level of TNFα was also significantly associated with advanced stage (stage III and IV) (p = 0.019), and high level of IL22 was significantly associated with a high histopathological grade (Grade III of Bloom-Richardson grade (SBR)) (p = 0.028). IL23 was found to be significantly increased in lymph node metastatic cases (p = 0.042) and in young patients < 35 years (p = 0.034). Finally, the level of IL17 was significantly higher in patients who had recurrent disease (p = 0.018). Conclusions: Our results highlight the role of certain circulating cytokines as potential prognostic biomarkers in breast cancer patients. The serum analysis of these cytokines, which could contribute to tumor growth and progression, may help to identify groups of patients with poor prognosis and who may need more aggressive treatment. This correlation needs to be evaluated in large prospective validating trials and suggests a rational for the development and use of cytokine blockade in treatment of some groups of breast cancer patients.
Collapse
Affiliation(s)
| | - Shourouk Haj Ammar
- Department of Oncology, Military Hospital of Tunis, Tunisia (University of Tunis Elmanar, FMT), Tunis, Tunisia
| | - Mehdi Balti
- Department of Oncology, Military Hospital of Tunis, Tunisia (University of Tunis Elmanar, FMT), Tunis, Tunisia
| | - Mouna Ben Azaiz
- Immunology Department, Military Hospital of Tunis (University of Tunis Elmanar, FMT), Tunis, Tunisia
| | - Aref Zribi
- Department of Oncology, Military Hospital of Tunis, Tunisia (University of Tunis Elmanar, FMT), Tunis, Tunisia
| | - Sana Fendri
- Department of Oncology, Military Hospital of Tunis, Tunisia (University of Tunis Elmanar, FMT), Tunis, Tunisia
| | - Sonia Ben Nasr
- Department of Oncology, Military Hospital of Tunis, Tunisia (University of Tunis Elmanar, FMT), Tunis, Tunisia
| | - Ezzedine Ghazouani
- Immunology Department, Military Hospital of Tunis (University of Tunis Elmanar, FMT), Tunis, Tunisia
| | - Faida Agili
- Research Unity of Military Hospital of Tunis, Tunis, Tunisia
| | | | - Abderrazek Haddaoui
- Department of Oncology, Military Hospital of Tunis, Tunisia (University of Tunis Elmanar, FMT), Tunis, Tunisia
| |
Collapse
|
3
|
Ayari JB, Guesmi R, Balti M, Ben Azaiz M, Zribi A, Fendri S, Ben Nasr S, Ghazouani E, Agili F, Kullab SA, Haddaoui A. Prognostic value of circulating cytokines in colorectal cancer: A prospective study in sixty colorectal cancer patients in Tunisia. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.e15130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e15130 Background: Colorectal cancer is the third most common malignancy and fourth most common cause of cancer mortality worldwide. It is responsible for more than 600,000 deaths annually, and incidence rates are increasing in most of the developing countries. Pathophysiology implicates pro-inflammatory conditions that promote the tumor malignant progression, invasion, and metastasis. The aim of this study is to measure the level of circulating cytokines (IL1b, IL6, IL8, IL10, IL22, IL23 and TNFα) in sixty colorectal cancer patients in Tunisia and to evaluate their implication as prognostic factors. Methods: Serum samples were collected prospectively from a cohort of sixty colorectal cancer patients in Tunisia. Levels of circulating inflammatory cytokines, TNF-α, IL1b, IL6 and IL8 were measured using the technique of a solid-phase, two-site chemo-luminescent enzyme immune-metric assay (Immulite 1000, Simens, USA). Serum levels of IL10 were measured by enzyme-linked immunosorbent assays (ELISA) sandwich method. Results: The mean age of patients is 58 years (24–82 years), Thirty-sex among them were m and 24 women with sex ratio of 1.5. Twenty-five patients were at metastatic setting, and hepatic metastasis was found in 25% of cases. The mean level of cytokines Il6, IL10, TNFα, IL8 and IL1b were respectively 12.26 +/- 18.7 pg/ ml (min 2, max 117pg/ ml), 0.93 +/- 5.23 pg/ ml (min 0, max 39.35 pg/ml), 8.31 +/- 4.99 pg/ ml (min 4, max 27.20 pg/ ml), 61.9 +/- 159.71 pg/ml (min 5, max 1173 pg/ ml) and 1.13 +/- 3.34 pg/ ml (min 5, max 15.7pg/ml. We found a significant correlation between a high level of IL8 and metastatic disease (p=0.001), especially in mutant RAS cases (p=0.001). We found also a significant correlation between high level of IL1b and lymphovascular invasion (p=0.013) and young patients (p=0.01). On the other hand, there was significant correlation between IL8 and IL6 (r = 0.560, p = 0.00001); IL8 and TNFα (r = 0.404, p = 0.001); and IL10 with IL1b (r = 0.297, p = 0.021). Conclusions: Our results highlight the role of circulating IL8, TNFα, IL1b and IL10 as potential prognostic biomarkers in colorectal cancer patients. These cytokines could contribute to tumor growth and progression, namely for IL-8 level that was significantly correlated with poor prognosis and advanced stages. This correlation needs to be evaluated in large prospective trials and suggests a rational for the development and use of cytokine blockade in treatment of colorectal cancer patients.
Collapse
Affiliation(s)
| | - Rania Guesmi
- Department of oncology, Military hospital of Tunis, Tunisia (University of Tunis Elmanar, FMT), Tunis, Tunisia
| | - Mehdi Balti
- Department of Oncology, Military Hospital of Tunis, Tunisia (University of Tunis Elmanar, FMT), Tunis, Tunisia
| | - Mouna Ben Azaiz
- Immunology Department, Military Hospital of Tunis (University of Tunis Elmanar, FMT), Tunis, Tunisia
| | - Aref Zribi
- Department of Oncology, Military Hospital of Tunis, Tunisia (University of Tunis Elmanar, FMT), Tunis, Tunisia
| | - Sana Fendri
- Department of Oncology, Military Hospital of Tunis, Tunisia (University of Tunis Elmanar, FMT), Tunis, Tunisia
| | - Sonia Ben Nasr
- Department of Oncology, Military Hospital of Tunis, Tunisia (University of Tunis Elmanar, FMT), Tunis, Tunisia
| | - Ezzedine Ghazouani
- Immunology Department, Military Hospital of Tunis (University of Tunis Elmanar, FMT), Tunis, Tunisia
| | - Faida Agili
- Research Unity of Military Hospital of Tunis, Tunis, Tunisia
| | | | - Abderrazek Haddaoui
- Department of Oncology, Military Hospital of Tunis, Tunisia (University of Tunis Elmanar, FMT), Tunis, Tunisia
| |
Collapse
|